Skip to main content
Marksans Pharma Ltd. logo

Marksans Pharma Ltd. - Investor Relations & Filings

Listed
Ticker · MARKSANS ISIN · INE750C01026 LEI · 335800YXQPMPSAC51K30 BSE.NS Manufacturing
Open in API
Filings indexed 779 across all filing types
Latest filing 2026-05-26 Investor Presentation
Country IN India
Listing BSE.NS MARKSANS · 2 venues

Key figures FY2026

Period ended 2026-03-31 · INR
Headline annual figures for Marksans Pharma Ltd., fiscal year 2026, reported in INR, with the source filing for each figure.
Total Revenues INR 13.41B per the Annual Report filed 2026-06-26
Net Income INR 3.01B per the Annual Report filed 2026-06-26
Total Assets INR 19.94B per the Annual Report filed 2026-06-26
Total Equity INR 16.52B per the Annual Report filed 2026-06-26
Cash from Ops INR 2.11B per the Annual Report filed 2026-06-26

As reported by the issuer in the filings linked above. Figures are normalized for comparability; consult the source filing for the authoritative statement.

About Marksans Pharma Ltd.

https://www.marksanspharma.com

Marksans Pharma Ltd. specializes in the research, development, and large-scale manufacturing of generic formulations. The company’s therapeutic focus spans pain management, cardiovascular health, central nervous system disorders, anti-diabetics, and gastrointestinal treatments. Its product portfolio includes diverse delivery systems such as solid orals, soft gelatin capsules, and liquid formulations, serving both the over-the-counter and prescription markets. The organization operates advanced manufacturing facilities compliant with international regulatory standards, facilitating a robust supply chain across major global markets including North America, Europe, and Australia. By integrating comprehensive research and development with efficient production processes, the company provides a broad range of high-quality, cost-effective medicinal products to a global patient base.

Recent filings

Filing Released Lang Actions
Investors Presentation Q4 FY26
Investor Presentation Classification · 96% confidence The document is a slide presentation titled “Investor Presentation” for Q4 FY26, filed pursuant to SEBI LODR Regulation 30. It contains detailed business and financial highlights, segment and geographic analysis, strategic initiatives, and outlook. It is not a statutory annual or interim report, earnings press release, or regulatory notice, but a comprehensive investor slide deck. This matches the definition of an Investor Presentation (Code: IP).
2026-05-26 English
Dividend
Audit Report / Information Classification · 92% confidence The document is a regulatory announcement under SEBI Listing Regulations that encloses the Audited Financial Results (Stand-alone and Consolidated) for the year ended March 31, 2026 along with the Statutory Auditor’s Independent Auditor’s Report. It is not a full annual report (10-K) nor merely a brief earnings release; rather, it is a standalone audit report with accompanying financial statements. Therefore it best fits the “Audit Report / Information” category. FY 2026
2026-05-26 English
Audited Financial Results for the quarter and year ended 31 March, 2026
Interim / Quarterly Report Classification · 90% confidence The document is headed “Outcome of Board Meeting” and contains the Audited Financial Results (Standalone and Consolidated) for the quarter and year ended March 31, 2026 along with the Statutory Auditor’s Report and the full financial statements. It is not a full annual report (10-K), nor is it merely a summary earnings release, nor an announcement that a report is available. Rather, it provides comprehensive interim/quarterly (and year‐end) financial results and the auditor’s report, fitting the definition of an Interim / Quarterly Report. FY 2026
2026-05-26 English
Outcome of Board Meeting
Audit Report / Information Classification · 91% confidence The document is a formal Board Meeting outcome filing to stock exchanges under SEBI Listing Regulations, enclosing the Audited Financial Results for the quarter and full year ended March 31, 2026 along with the full Independent Auditor’s Report and detailed financial statement tables. It is not merely a brief earnings release (ER) or a notice of publication (RPA), but contains the complete audited financials and statutory auditor’s opinion. This fits the definition of a standalone Audit Report / Information filing (AR) rather than a full narrative Annual Report (10-K) or interim report. FY 2026
2026-05-26 English
Outcome of Board Meeting held on 26 May, 2026
Interim / Quarterly Report Classification · 75% confidence The document is a regulatory filing under SEBI Listing Regulations (Reg 33 and Reg 30) conveying the Board’s approval of the Audited Financial Results (Standalone and Consolidated) for the quarter and financial year ended March 31, 2026, and includes the full auditor’s report and detailed financial statements. This is more than a brief earnings highlight, and it contains substantive quarter-end and year-end results rather than a mere notice of publication. Under our taxonomy, this type of comprehensive periodic financial results disclosure corresponds to an Interim/Quarterly Report (IR). FY 2026
2026-05-26 English
ESOP/ESOS/ESPS
Share Issue/Capital Change Classification · 85% confidence The document is an official disclosure under SEBI Listing Regulations informing stock exchanges of the grant of 300,000 employee stock options under the Marksans Employees Stock Option Scheme 2024. This pertains to potential issuance of new equity shares upon option exercise, and therefore falls under Share Issue/Capital Change announcements rather than an actual financial report, call transcript, management change, or earnings release. It is not a simple report publication notice or certification but a substantive capital action disclosure under Regulation 30.
2026-05-25 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.